Gilead Sciences, Inc. $GILD Shares Purchased by Avidian Wealth Enterprises LLC

Avidian Wealth Enterprises LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,044 shares of the biopharmaceutical company’s stock after purchasing an additional 367 shares during the quarter. Avidian Wealth Enterprises LLC’s holdings in Gilead Sciences were worth $1,114,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Southland Equity Partners LLC boosted its holdings in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares during the period. Twelve Points Wealth Management LLC lifted its position in shares of Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 98 shares in the last quarter. Argentarii LLC boosted its stake in shares of Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 99 shares during the period. Lodestar Private Asset Management LLC grew its holdings in Gilead Sciences by 3.6% during the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 100 shares in the last quarter. Finally, RDA Financial Network increased its stake in Gilead Sciences by 5.1% during the 2nd quarter. RDA Financial Network now owns 2,129 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 103 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock valued at $8,281,540 over the last three months. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.8%

Shares of GILD opened at $124.08 on Wednesday. Gilead Sciences, Inc. has a 1-year low of $85.60 and a 1-year high of $124.61. The business’s 50-day moving average price is $115.35 and its 200 day moving average price is $110.71. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $153.96 billion, a P/E ratio of 24.72, a P/E/G ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the business posted $2.01 EPS. The company’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Citigroup increased their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. The Goldman Sachs Group raised their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $121.14.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.